Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 11Recruiting 8Active not recruiting 5Terminated 4Unknown 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Carcinoma, Non-Small-Cell Lung 103Lung Neoplasms 49Ovarian Neoplasms 44Breast Neoplasms 31Small Cell Lung Carcinoma 25Neoplasms 20Fallopian Tube Neoplasms 16Triple Negative Breast Neoplasms 14Carcinoma, Ovarian Epithelial 14Neoplasm Metastasis 12Adenocarcinoma of Lung 11Uterine Cervical Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Non-Hodgkin 7Lymphoma 7Head and Neck Neoplasms 7Carcinoma 7Urinary Bladder Neoplasms 6Esophageal Neoplasms 6Endometrial Neoplasms 6Brain Neoplasms 6Thoracic Neoplasms 5Prostatic Neoplasms 5Melanoma 5Lung Diseases 5Adenocarcinoma Of Esophagus 5Adenocarcinoma 5Respiratory Tract Neoplasms 4Recurrence 4

Interventions

pembrolizumab 20atezolizumab 9Nivolumab 9Gemcitabine 9Docetaxel 5avelumab 4Mitomycin 4Carboplatin 4fludarabine 3epacadostat 3enfortumab vedotin 3Cyclophosphamide 3vofatamab 2valrubicin 2rucaparib 2pemigatinib 2durvalumab 2cabozantinib 2Standard of Care 2Sirolimus 2Radiation 2Pemetrexed 2Cisplatin 2Bevacizumab 2B701 protein, Human herpesvirus 6 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2trilaciclib 1temsirolimus 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Transitional Cell × Carboplatin × Clear all
NCT03288545 2026-03-24

EV-103

Astellas Pharma Inc

Phase 1/2 Terminated
348 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Incyte Corporation

Phase 2 Terminated
7 enrolled 10 charts
Genitourinary

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT04887831 2025-09-08

PRESERVE3

G1 Therapeutics, Inc.

Phase 2 Terminated
92 enrolled 24 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03737123 2023-09-13

Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Hoosier Cancer Research Network

Phase 2 Terminated
6 enrolled 18 charts
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡